Chimeric Therapeutics is trading at A$0.05, down 5.45% today following the announcement of a strategic review and changes to its board of directors.
- The company initiated a strategic review on July 1, 2026, aimed at maximizing shareholder value.
- Independent non-executive director Eric Sullivan is set to retire from the board on July 6, 2026.
- These governance developments and the strategic pivot are drawing significant investor attention and may be weighing on market sentiment.